Financhill
Sell
22

GALT Quote, Financials, Valuation and Earnings

Last price:
$1.33
Seasonality move :
40.01%
Day range:
$1.25 - $1.33
52-week range:
$0.73 - $4.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
131.6K
Avg. volume:
368.3K
1-year change:
-21.08%
Market cap:
$82.2M
Revenue:
--
EPS (TTM):
-$0.73

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Upside
    No price target exists because of limited analyst coverage.
  • Price Target Downside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Galectin Therapeutics has 739.7% upside to fair value with a price target of -- per share.

GALT vs. S&P 500

  • Over the past 5 trading days, Galectin Therapeutics has overperformed the S&P 500 by 0.34% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Galectin Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Galectin Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Galectin Therapeutics reported revenues of --.

Earnings Growth

  • Galectin Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Galectin Therapeutics reported earnings per share of -$0.18.
Enterprise value:
161.9M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.81x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$35.1M -$39.1M -$39.6M -$9.2M -$9.1M
EBITDA -$34.3M -$39.4M -$40.4M -$9.6M -$9.7M
Diluted EPS -$0.59 -$0.76 -$0.73 -$0.24 -$0.18
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $33.9M $38M $17.1M $21.6M $28.7M
Total Assets $34M $38M $17.9M $22.2M $29M
Current Liabilities $2.5M $8.3M $9.6M $10.5M $25.3M
Total Liabilities $2.5M $28.8M $40.2M $73M $121.5M
Total Equity $31.5M $9.2M -$22.3M -$50.9M -$92.5M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$30.8M -$35.5M -$33.7M -$7.6M -$8.5M
Cash From Investing -- -- -- -- --
Cash From Financing $10M $40M $40.4M $10M $10M
Free Cash Flow -$30.8M -$35.5M -$33.7M -$7.6M -$8.5M
GALT
Sector
Market Cap
$82.2M
$43.3M
Price % of 52-Week High
30.69%
47.98%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
-21.08%
-36.92%
Beta (5-Year)
0.816
0.753
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $1.29
200-day SMA
Sell
Level $2.36
Bollinger Bands (100)
Sell
Level 1.38 - 2.8
Chaikin Money Flow
Sell
Level -141.3M
20-day SMA
Buy
Level $1.26
Relative Strength Index (RSI14)
Sell
Level 48.22
ADX Line
Buy
Level 8.76
Williams %R
Sell
Level -17.2414
50-day SMA
Sell
Level $1.49
MACD (12, 26)
Sell
Level -0.04
25-day Aroon Oscillator
Buy
Level 76
On Balance Volume
Neutral
Level 239.9M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Stock Forecast FAQ

In the current month, GALT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GALT average analyst price target in the past 3 months is --.

  • Where Will Galectin Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Galectin Therapeutics share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Galectin Therapeutics?

    Analysts are divided on their view about Galectin Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Galectin Therapeutics is a Sell and believe this share price will drop from its current level to --.

  • What Is Galectin Therapeutics's Price Target?

    The price target for Galectin Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is GALT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Galectin Therapeutics is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of GALT?

    You can purchase shares of Galectin Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Galectin Therapeutics shares.

  • What Is The Galectin Therapeutics Share Price Today?

    Galectin Therapeutics was last trading at $1.33 per share. This represents the most recent stock quote for Galectin Therapeutics. Yesterday, Galectin Therapeutics closed at $1.31 per share.

  • How To Buy Galectin Therapeutics Stock Online?

    In order to purchase Galectin Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
58
UPST alert for Feb 13

Upstart Holdings [UPST] is up 31.82% over the past day.

Buy
79
CFLT alert for Feb 13

Confluent [CFLT] is up 24.92% over the past day.

Buy
52
BL alert for Feb 13

BlackLine [BL] is down 18.03% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock